T cells

[Gracell Biotechnologies, Inc.] Gracell Biotechnologies, Inc. announced an exclusive license agreement with FutureGen Biopharm to develop engineered immune cell therapies targeting Claudin 18.2, a tumor-specific marker that is overexpressed in a variety of tumor tissues, including in gastric or gastroesophageal junction cancers.

[European Journal of Medical Research] The BxPC-3-DKK3 cell line was constructed, and peripheral blood mononuclear cell was prepared. After isolated the CD4+ T cells, the lactic acid, glucose uptake ability, cellular viability, proliferation, apoptosis, and markers were detected by PCR and western blot, and the concentrations of multiple cytokines were determined using the ELISA method.

[Blood Cancer Journal] The authors found that interleukin-10 receptor (IL-10R) was overexpressed in most acute myeloid luekemia cells, and played an important role in promoting the stemness of leukemia cells.

[British Journal of Cancer] Scientists review the co-inhibitory pathways that are known to suppress intratumoral T cells in hepatocellular carcinoma and cholangiocarcinoma.

[Immunity] Researchers performed longitudinal antigen-specific T cell analyses on healthy SARS-CoV-2 naïve and recovered individuals prior to and following mRNA prime and boost vaccination.

[Gene Therapy] CAR T cells were designed using a ligand binding domain instead of a single chain variable fragments to target stem-like leukemia cells. Thrombopoietin, the natural ligand to the myeloproliferative leukemia protein (MPL) receptor, was used as the antigen binding domain to engage MPL expressed on HSCs and erythropoietic and megakaryocytic acute myeloid leukemias.